Eurofins-Cerep SA
ALECR
Company Profile
Business description
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
Contact
Le bois l Eveque
Celle l Evescault86600
FRAT: +33 549893000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
207
Stocks News & Analysis
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
stocks
3 global ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,120.90 | 34.10 | 0.38% |
| CAC 40 | 7,896.93 | 71.69 | 0.92% |
| DAX 40 | 23,748.86 | 50.71 | 0.21% |
| Dow JONES (US) | 45,856.28 | 22.06 | 0.05% |
| FTSE 100 | 9,277.03 | 6.26 | -0.07% |
| HKSE | 26,446.56 | 58.40 | 0.22% |
| NASDAQ | 22,310.09 | 168.98 | 0.76% |
| Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
| NZX 50 Index | 13,208.31 | 19.59 | -0.15% |
| S&P 500 | 6,607.65 | 23.36 | 0.35% |
| S&P/ASX 200 | 8,853.00 | 31.60 | 0.36% |
| SSE Composite Index | 3,860.50 | 10.09 | -0.26% |